Table 1 GS samples with stress-related phenotypes

From: Genome-wide by environment interaction studies of depressive symptoms and psychosocial stress in UK Biobank and Generation Scotland

Trait

N

Males/females

N SNPs

N Cases

N Controls

Alzheimer (R)

3377

1475/1903

560,622

655

2722

Asthma

3390

1500/1890

560,569

555

2835

Asthma (R)

3375

1470/1905

560,432

910

2465

Bowel cancer (R)

3386

1495/1891

560,630

672

2714

Breast cancer

3388

1486/1902

560,611

83

3305

Breast cancer (R)

3386

1482/1904

560,579

564

2822

Chronic obstructive pulmonary disease

3387

1496/1891

560,591

73

3314

Chronic obstructive pulmonary disease (R)

3387

1474/1913

560,620

553

2834

Depression

3385

1495/1890

560,584

483

2902

Depression (R)

3382

1506/1876

560,514

731

2651

Diabetes

3388

1497/1891

560,469

185

3203

Diabetes (R)

3389

1481/1908

560,584

1144

2245

Heart disease

3392

1504/1888

560,526

212

3180

Heart disease (R)

3377

1483/1894

560,479

2254

1123

High blood pressure

3402

1501/1901

560,508

729

2673

High blood pressure (R)

3372

1464/1908

560,569

1901

1471

Hip fracture (R)

3388

1489/1899

560,572

421

2967

Lung cancer (R)

3379

1492/1887

560,600

798

2581

Osteoarthritis

3395

1486/1909

560,640

411

2984

Osteoarthritis (R)

3383

1466/1917

560,516

961

2422

Parkinson (R)

3388

1488/1900

560,590

236

3152

Prostate cancer (R)

3381

1495/1886

560,570

329

3052

Rheumatoid arthritis

3387

1490/1897

560,618

93

3294

Rheumatoid arthritis (R)

3380

1487/1893

560,543

765

2615

Stroke

3387

1492/1895

560,613

81

3306

Stroke (R)

3385

1463/1922

560,478

1506

1879

Neuroticisma

3421

1521/1900

560,484

–

–

Extraversiona

3420

1520/1900

560,476

–

–

Schizotypal personalitya

2386

1065/1321

560,369

–

–

Mood disordera

2307

1040/1267

560,318

–

–

  1. Samples were maximised for retention of cases to maximise the information available for each trait. There was no preferential selection of relatives in pairs for quantitative phenotypes, in order to retain the underlying distribution. All individuals involved in the datasets listed above were non-respondents to the GS follow-up study. Compared with individuals included at GS GWEIS (respondents in GS follow-up), non-respondents were significantly: younger, from more socioeconomically deprived areas, generally less healthier and wealthier. Non-respondents were more likely to smoke, and less likely to drink alcohol, although they consumed more units per week, compared with respondents. At GS baseline, non-respondents experienced more psychological distress and reported higher scores in symptoms of GHQ-depression and GHQ-anxiety than respondents56
  2. The total target sample size (N), number of males and females in N, number of SNPs (N SNPs) in target sample size N: the number of SNPs used as predictors after clumping step range between 90,650 and 91,000. The number of cases and controls in the independent target sample is indicated for binary phenotypes only. Samples were mapping by proxy approach was used (i.e., where first-degree relatives of individuals with the disease were considered proxy cases and included into the group of cases) are indicated by (R)
  3. GS Generation Scotland, GWEIS genome-wide by environment interaction studies, GHQ General Health Questionnaire
  4. aAssessed through self-reported questionnaires
Back to article page